Dr. Scott S. Tykodi, MD reveals the results of the Checkmate – 214 trial with combined immunotherapy nivolumab plus ipilimumab and explains the positive results on objective response rate and prolonged progression-free survival compared to sunitinib in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma.
